Rabeprazole Sodium
Product Images NDC 50090-3145

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Rabeprazole Sodium (NDC 50090-3145). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500903145)

Label for Rabeprazole Sodium 20 mg delayed release tablets. The package contains 30 tablets. Labeler is A-S Medication Solutions, LLC. Instructions include storing at 77 degrees Fahrenheit and protecting from moisture. Additional identifiers include Product No. 6489-0 and NDC 50090-3145-0.*

FDA Label Image

Figure 1 (Rabeprazole Sodium Delayed Release Tablets 1)

Chemical structure of Rabeprazole Sodium showing its molecular arrangement, including a benzene ring fused to a pyridine and sulfur-containing moiety, with various functional groups attached.*

FDA Label Image

Figure 2 (Rabeprazole Sodium Delayed Release Tablets 2)

A line graph displaying mean heartburn scores over a 28-day study period, comparing placebo with Rabeprazole Sodium (RAB) at 10 mg and 20 mg doses. The x-axis shows study days from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). Separate lines represent placebo, RAB 10 mg, and RAB 20 mg groups.*

FDA Label Image

Figure 3 (Rabeprazole Sodium Delayed Release Tablets 3)

Line graph showing mean heartburn scores over a 28-day study period comparing placebo, Rabeprazole sodium 10 mg, and Rabeprazole sodium 20 mg groups. The x-axis represents study days from -14 to 28, and the y-axis indicates mean heartburn scores ranging from 0 (None) to 4 (Very Severe). The graph depicts a decrease in heartburn scores post-treatment initiation (day 0) for Rabeprazole groups compared to placebo.*

FDA Label Image

Figure 4 (Rabeprazole Sodium Delayed Release Tablets 4)

A line graph comparing mean heartburn scores over time between a placebo group (n=58) and a Rabeprazole Sodium 20 mg group (n=59). The x-axis shows study days from -14 to 28, and the y-axis shows mean heartburn scores from 0 (none) to 4 (very severe). The graph illustrates a decrease in scores for the Rabeprazole group after day 0 compared to placebo.*

FDA Label Image

Figure 5 (Rabeprazole Sodium Delayed Release Tablets 5)

A line graph comparing mean heartburn scores over a 28-day study period between a placebo group (n=58) and a group receiving Rabeprazole Sodium 20 mg (n=59). The x-axis represents study days from -14 to 28, and the y-axis shows mean scores from 0 (none) to 4 (very severe). The Rabeprazole group shows consistently lower mean scores post-treatment compared to placebo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.